Close

Anti-TNFRSF8 Antibody scFv (MOM-18153-S(P))

DESCRIPTION CATALOG # SIZE PRICE
Recombinant Anti-Human TNFRSF8 Antibody scFv Fragment MOM-18153-S(P) 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant Chimeric (mouse/human) Antibody scFv Fragment is directed against Human CD30, expressed in E. coli
  • Target
  • CD30
  • Type
  • scFv Fragment from Chimeric (mouse/human) IgG1 - kappa
  • Immunogen
  • Hodgkin's lymphoma cell line L428.
  • Species Reactivity
  • Human
  • Expression Host
  • E. coli
  • Applications
  • Suitable for use in ELISA, WB, Neut and most other immunological methods.
  • Specific Activity
  • Tested positive against native antigen.
  • Purity
  • >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

BACKGROUND

  • Antigen Description
  • Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.
  • Function
  • binding; receptor activity; transmembrane signaling receptor activity; tumor necrosis factor-activated receptor activity;
  • Synonyms
  • TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30, D1S166E; tumor necrosis factor receptor superfamily member 8; KI 1; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30; CD30; Ki-1; D1S166E;

Related Products

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us